Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Survey of Health Care Professionals on the Food Safety and Nutrition Information That They Provide to Pregnant Women, 13117-13118 [E7-5046]

Download as PDF Federal Register / Vol. 72, No. 53 / Tuesday, March 20, 2007 / Notices has submitted the following proposed collection of information to OMB for review and clearance. DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. 2006N–0187] Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Survey of Health Care Professionals on the Food Safety and Nutrition Information That They Provide to Pregnant Women AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995. DATES: Fax written comments on the collection of information by April 19, 2007. To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–6974. FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief Information Officer (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827– 4659. ADDRESSES: In compliance with 44 U.S.C. 3507, FDA SUPPLEMENTARY INFORMATION: Survey of Health Care Professionals on the Food Safety and Nutrition Information That They Provide to Pregnant Women Under section 903(b)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 393(b)(2)), FDA is authorized to conduct research relating to foods and to conduct educational and public information programs relating to the safety of the nation’s food supply. FDA is planning to conduct a survey of health care professionals to determine what information, advice, and recommendations they are offering to pregnant women about the following topics: (1) Methyl mercury and seafood consumption, (2) Listeriosis prevention, (3) weight control and nutrition, (4) dietary supplement usage, (5) food allergies, (6) Toxoplasmosis prevention, and (7) infant feeding practices. FDA is interested in obtaining this data since FDA has recently issued advice for pregnant women about food safety risks and diet risks such as mercury in seafood, Listeriosis, and Toxoplamosis. (‘‘Food Safety for Moms-to-Be,’’ 2005 and ‘‘What You Need to Know about Mercury in Fish and Shellfish,’’ 2004). Data from this survey will be used to evaluate whether health care professionals are aware of this advice and if they are educating their patients about information in the FDA advisories. FDA will also use this survey to get a better understanding of what resources health care professionals use to stay abreast of current practices for caring for 13117 pregnant women. This will help FDA provide timely recommendations to health care professionals that will reach the largest audience. A sample of 400 obstetrician/ gynecologists, 200 nurse practitioners, 200 nurse midwives, 200 physician assistants, and 200 dietitians from the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) will be included in this survey. The sample of nurse practitioners, nurse midwives, and physician assistants will be drawn from those specializing in obstetrics. The samples will be randomly selected from lists obtained from national associations. The survey will be conducted using a mailed questionnaire. Cognitive interviews and a pretest will be conducted prior to fielding the survey. In the Federal Register of June 2, 2006 (71 FR 32095), FDA published a 60-day notice requesting public comment on the information collection provisions. FDA received one comment responsive to the comment request. (Comment) The comment suggests that FDA should expand the respondent universe of the survey to include all categories of health care providers that care for pregnant women. (Response) FDA agrees that the survey universe should include samples drawn from all categories of health care providers that provide care for pregnant women. The current sampling plan calls for samples of 400 obstetrician/ gynecologists, 200 nurse practitioners, 200 certified nurse midwives, 200 physician assistants, and 200 WIC nutrition educators. TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1 Annual Frequency Per Response No. of Respondents Total Annual Responses Hours Per Response Total Hours 1,200—Survey 1 1,200 .167 200.4 75—Pretest 1 75 .167 12.5 16—Cognitive Interview 1 16 .75 12 Total 1 1,291 pwalker on PROD1PC71 with NOTICES 1There 224.9 are no capital costs or operating and maintenance costs associated with this collection of information. VerDate Aug<31>2005 15:08 Mar 19, 2007 Jkt 211001 PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 E:\FR\FM\20MRN1.SGM 20MRN1 13118 Federal Register / Vol. 72, No. 53 / Tuesday, March 20, 2007 / Notices Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Katherine Woodbury, PhD, Scientific Review Administrator, Scientific Review Branch, NINDS/NIH/ DHHS, Neuroscience Center, 6001 Executive Blvd., Suite 3208, MSC 9529, Bethesda, MD 20892–9529, (301) 496– 5980, kw47o@nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. The burden estimate is based on FDA’s experience with previous surveys. Dated: March 15, 2007. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E7–5046 Filed 3–19–07; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health pwalker on PROD1PC71 with NOTICES National Institute of Neurological Disorders and Stroke; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, Survival Skills and Ethics. Date: March 28, 2007. Time: 11 a.m. to 12 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Phillip F. Wiethorn, Scientific Review Administrator, DHHS/ NIH/NINDS/DER/SRB, 6001 Executive Boulevard, MSC 9529, Neuroscience Center, Room 3203, Bethesda, MD 20892–9529, (301) 496–5388, wiethorp@ninds.nih.gov. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel, Migraine. Date: April 10, 2007. Time: 10 a.m. to 2 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Neuroscience Center, 6001 Executive VerDate Aug<31>2005 16:34 Mar 19, 2007 Jkt 211001 (Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS.) Dated: March 14, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1345 Filed 3–19–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, DNA Looping. Date: April 18, 2007. Time: 3:30 p.m. to 4:30 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6100 Executive Boulevard, 5B01, Rockville, MD 20852 (Telephone Conference Call). Contact Person: Norman Chang, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health and Human Development, NIH, 6100 Executive Blvd., Room 5B01, Bethesda, MD 20892. (301) 496–1485. changn@mail.nih.gov. PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS.) Dated: March 13, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1348 Filed 3–19–07; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Child Health and Human Development; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Child Health and Human Development Special Emphasis Panel, Developmental Infrastructure For Population Research. Date: April 12–13, 2007. Time: 9 a.m. to 7 p.m. Agenda: To review and evaluate grant applications. Place: Hotel Washington, 515 15th Street, NW., Council Room, Washington, DC 20004. Contact Person: Marita R. Hopmann, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health, and Human Development, 6100 Building, Room 5B01, Bethesda, MD 20892. (301) 435–6911. hopmannm@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS.) Dated: March 13, 2007. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–1349 Filed 3–19–07; 8:45 am] BILLING CODE 4140–01–M E:\FR\FM\20MRN1.SGM 20MRN1

Agencies

[Federal Register Volume 72, Number 53 (Tuesday, March 20, 2007)]
[Notices]
[Pages 13117-13118]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-5046]



[[Page 13117]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2006N-0187]


Agency Information Collection Activities; Submission for Office 
of Management and Budget Review; Comment Request; Survey of Health Care 
Professionals on the Food Safety and Nutrition Information That They 
Provide to Pregnant Women

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that a 
proposed collection of information has been submitted to the Office of 
Management and Budget (OMB) for review and clearance under the 
Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by April 
19, 2007.

ADDRESSES: To ensure that comments on the information collection are 
received, OMB recommends that written comments be faxed to the Office 
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, 
FAX: 202-395-6974.

FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of the Chief 
Information Officer (HFA-250), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, 301-827-4659.

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has 
submitted the following proposed collection of information to OMB for 
review and clearance.

Survey of Health Care Professionals on the Food Safety and Nutrition 
Information That They Provide to Pregnant Women

    Under section 903(b)(2) of the Federal Food, Drug, and Cosmetic Act 
(21 U.S.C. 393(b)(2)), FDA is authorized to conduct research relating 
to foods and to conduct educational and public information programs 
relating to the safety of the nation's food supply. FDA is planning to 
conduct a survey of health care professionals to determine what 
information, advice, and recommendations they are offering to pregnant 
women about the following topics: (1) Methyl mercury and seafood 
consumption, (2) Listeriosis prevention, (3) weight control and 
nutrition, (4) dietary supplement usage, (5) food allergies, (6) 
Toxoplasmosis prevention, and (7) infant feeding practices. FDA is 
interested in obtaining this data since FDA has recently issued advice 
for pregnant women about food safety risks and diet risks such as 
mercury in seafood, Listeriosis, and Toxoplamosis. (``Food Safety for 
Moms-to-Be,'' 2005 and ``What You Need to Know about Mercury in Fish 
and Shellfish,'' 2004). Data from this survey will be used to evaluate 
whether health care professionals are aware of this advice and if they 
are educating their patients about information in the FDA advisories.
    FDA will also use this survey to get a better understanding of what 
resources health care professionals use to stay abreast of current 
practices for caring for pregnant women. This will help FDA provide 
timely recommendations to health care professionals that will reach the 
largest audience.
    A sample of 400 obstetrician/gynecologists, 200 nurse 
practitioners, 200 nurse midwives, 200 physician assistants, and 200 
dietitians from the Special Supplemental Nutrition Program for Women, 
Infants, and Children (WIC) will be included in this survey. The sample 
of nurse practitioners, nurse midwives, and physician assistants will 
be drawn from those specializing in obstetrics. The samples will be 
randomly selected from lists obtained from national associations. The 
survey will be conducted using a mailed questionnaire. Cognitive 
interviews and a pretest will be conducted prior to fielding the 
survey.
    In the Federal Register of June 2, 2006 (71 FR 32095), FDA 
published a 60-day notice requesting public comment on the information 
collection provisions. FDA received one comment responsive to the 
comment request.
    (Comment) The comment suggests that FDA should expand the 
respondent universe of the survey to include all categories of health 
care providers that care for pregnant women.
    (Response) FDA agrees that the survey universe should include 
samples drawn from all categories of health care providers that provide 
care for pregnant women. The current sampling plan calls for samples of 
400 obstetrician/gynecologists, 200 nurse practitioners, 200 certified 
nurse midwives, 200 physician assistants, and 200 WIC nutrition 
educators.

                                 Table 1.--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
                                   Annual Frequency       Total Annual         Hours Per
       No. of Respondents            Per Response          Responses           Response           Total Hours
----------------------------------------------------------------------------------------------------------------
1,200--Survey                                       1              1,200                .167               200.4
----------------------------------------------------------------------------------------------------------------
75--Pretest                                         1                 75                .167                12.5
----------------------------------------------------------------------------------------------------------------
16--Cognitive Interview                             1                 16                .75                 12
----------------------------------------------------------------------------------------------------------------
Total                                               1              1,291  ..................               224.9
----------------------------------------------------------------------------------------------------------------
\1\There are no capital costs or operating and maintenance costs associated with this collection of information.


[[Page 13118]]

    The burden estimate is based on FDA's experience with previous 
surveys.

    Dated: March 15, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7-5046 Filed 3-19-07; 8:45 am]
BILLING CODE 4160-01-S
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.